Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 7, 2026, 11:40 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 553–576 of 10,627 matching trials from the live ClinicalTrials.gov search.

Filters: Pittsburgh, Pennsylvania Clear all

Conditions: Cervical Cancer
Interventions: da Vinci, open surgery; Device · Other
Lead sponsor: GOG Foundation; Network
Eligibility: 18 Years and older · Female only
Enrollment: 840 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2030
U.S. locations: 133
States / cities: Goodyear, Arizona • Duarte, California • Encinitas, California + 87 more

Conditions: Hemophilia A
Interventions: Not listed
Lead sponsor: BioMarin Pharmaceutical; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 172 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2040
U.S. locations: 13
States / cities: Los Angeles, California • Sacramento, California • San Diego, California + 10 more

Conditions: Neck Pain, Cervical Pain
Interventions: Manual Manipulation, Mobilization; Procedure
Lead sponsor: Keystone Rehabilitation Systems; Other
Eligibility: 18 Years to 60 Years
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 2
States / cities: Bridgeville, Pennsylvania • Pittsburgh, Pennsylvania

Conditions: Contrast Induced Nephropathy
Interventions: RenalGuard Therapy, Standard Therapy; Device · Drug
Lead sponsor: CardioRenal Systems, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 326 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2024
U.S. locations: 30
States / cities: Birmingham, Alabama • Torrance, California • Washington D.C., District of Columbia + 23 more

Conditions: Focal Epilepsy
Interventions: XEN1101; Drug
Lead sponsor: Xenon Pharmaceuticals Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 325 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2030
U.S. locations: 54
States / cities: Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 46 more

Conditions: Ovarian Cancer, Primary Peritoneal Cavity Cancer
Interventions: carboplatin, oglufanide disodium, paclitaxel, conventional surgery; Drug · Procedure
Lead sponsor: Cytran; Industry
Eligibility: 18 Years and older · Female only
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2001
U.S. locations: 19
States / cities: Glendale, California • Los Gatos, California • Stanford, California + 15 more

Conditions: Need for MRI Imaging With Pacemaker or, Implantable Cardioverter Defibrillator Implanted
Interventions: MRI with pacemaker or ICD; Device
Lead sponsor: Scripps Health; Other
Eligibility: 18 Years and older
Enrollment: 2,039 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2014
U.S. locations: 21
States / cities: Burbank, California • La Jolla, California • Los Angeles, California + 16 more

Conditions: HIV-1-infection
Interventions: SAR441236, Placebo; Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 70 Years
Enrollment: 52 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 23
States / cities: Birmingham, Alabama • Los Angeles, California • San Diego, California + 17 more

Conditions: Stage IIIA Non-Small Cell Lung Cancer
Interventions: Neoadjuvant Cisplatin, nab-paclitaxel, Adjuvant Cisplatin,nab-paclitaxel, Adjuvant cisplatin+pemetrexed or cisplatin+gemcitabine; Drug
Lead sponsor: UNC Lineberger Comprehensive Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 9
States / cities: Tampa, Florida • Atlanta, Georgia • Kansas City, Kansas + 6 more

Conditions: Hemophilia a, Hemophilia B
Interventions: SerpinPC; Drug
Lead sponsor: ApcinteX Ltd; Industry
Eligibility: 12 Years to 65 Years · Male only
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 10
States / cities: Aurora, Colorado • Tampa, Florida • Indianapolis, Indiana + 7 more

Conditions: Pain
Interventions: Alternative Keyboard; Device
Lead sponsor: University of Pittsburgh; Other
Eligibility: 18 Years to 65 Years
Enrollment: 85 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2013
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Cocaine Use Disorder
Interventions: Prize-Based Contingency Management, Treatment As Usual Outpatient Substance Use Treatment; Behavioral
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: 18 Years to 75 Years
Enrollment: 63 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2024
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Extrahepatic Bile Duct Cancer, Gallbladder Cancer, Liver Cancer
Interventions: becatecarin; Drug
Lead sponsor: Case Comprehensive Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 72 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1999 – 2005
U.S. locations: 3
States / cities: Birmingham, Alabama • Cleveland, Ohio • Pittsburgh, Pennsylvania

Conditions: Candidiasis
Interventions: Eraxis (anidulafungin), Diflucan (fluconazole), Vfend (voriconazole); Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 282 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2010
U.S. locations: 39
States / cities: Birmingham, Alabama • Little Rock, Arkansas • Los Angeles, California + 25 more

Conditions: Adult Rhabdomyosarcoma, Embryonal Childhood Rhabdomyosarcoma, Embryonal-botryoid Childhood Rhabdomyosarcoma, Previously Untreated Childhood Rhabdomyosarcoma
Interventions: conventional surgery, dactinomycin, cyclophosphamide, vincristine sulfate, radiation therapy; Procedure · Drug · Radiation
Lead sponsor: Children's Oncology Group; Network
Eligibility: Up to 49 Years
Enrollment: 390 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2021
U.S. locations: 138
States / cities: Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 113 more

Conditions: Chronic Obstructive Pulmonary Disease, Interstitial Lung Disease
Interventions: Lung biopsy/lobectomy; Procedure
Lead sponsor: National Heart, Lung, and Blood Institute (NHLBI); NIH
Eligibility: 21 Years and older
Enrollment: 247 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2019
U.S. locations: 4
States / cities: Ann Arbor, Michigan • Rochester, Minnesota • Philadelphia, Pennsylvania + 1 more

Conditions: Sclerosis, Systemic
Interventions: Placebo, tocilizumab [RoActemra/Actemra]; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older
Enrollment: 87 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2015
U.S. locations: 21
States / cities: Los Angeles, California • San Diego, California • Stanford, California + 18 more

Conditions: Candidemia, Mycoses, Fungal Infection, Invasive Candidiases
Interventions: Rezafungin for Injection, Caspofungin, Fluconazole, intravenous placebo, oral placebo; Drug
Lead sponsor: Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA); Industry
Eligibility: 18 Years and older
Enrollment: 199 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2021
U.S. locations: 19
States / cities: Birmingham, Alabama • Sacramento, California • Atlanta, Georgia + 16 more

Conditions: Spinal Cord Injuries, Spinal Cord Diseases
Interventions: HIIT; Other
Lead sponsor: University of Pittsburgh; Other
Eligibility: 18 Years to 65 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Hemophilia B
Interventions: Not listed
Lead sponsor: Spark Therapeutics, Inc.; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2017
U.S. locations: 2
States / cities: Philadelphia, Pennsylvania • Pittsburgh, Pennsylvania

Conditions: Chronic Obstructive Pulmonary Disease (COPD)
Interventions: Reldesemtiv, Placebo; Drug
Lead sponsor: Astellas Pharma Global Development, Inc.; Industry
Eligibility: 40 Years to 75 Years
Enrollment: 46 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 2
States / cities: Torrance, California • Pittsburgh, Pennsylvania

Conditions: HIV-1 Infection
Interventions: Pitavastatin, Placebos; Drug
Lead sponsor: Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections; Network
Eligibility: 40 Years to 75 Years
Enrollment: 602 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2023
U.S. locations: 30
States / cities: Birmingham, Alabama • Los Angeles, California • San Diego, California + 22 more

Conditions: Diabetes Mellitus, Type 2
Interventions: ITCA 650 20/60 mcg/day, Empagliflozin (oral), Glimepiride (oral); Drug
Lead sponsor: Intarcia Therapeutics; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 245 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 96
States / cities: Fountain Hills, Arizona • Glendale, Arizona • Phoenix, Arizona + 81 more

Conditions: Bleeding
Interventions: Andexanet; Biological
Lead sponsor: Alexion Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 479 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2020
U.S. locations: 23
States / cities: Long Beach, California • Los Angeles, California • Orange, California + 20 more

Search by objective public record fields.

A Trial of Robotic Versus Open Hysterectomy Surgery in Cervix Cancer

A Long-Term Follow-Up Study in Severe Hemophilia A Subjects Who Received BMN 270 in a Prior BioMarin Clinical Trial (270-401)

The Effects of Thoracic Spine Manipulation in Individuals With Non-traumatic Cervical Pain

Evaluation of RenalGuard® System to Reduce the Incidence of Contrast Induced Nephropathy in At-Risk Patients

A Study to Evaluate XEN1101 as Adjunctive Therapy in Focal Epilepsy

Combination Chemotherapy Plus IM-862 in Treating Patients With Resected Stage III Ovarian Cancer or Primary Peritoneal Cancer

The MagnaSafe Registry: Determining the Risks of Magnetic Resonance Imaging (MRI) in the Presence of Pacemakers and Implantable Cardioverter Defibrillators (ICDs)

Pharmacokinetics and Safety of SAR441236

Cisplatin and Nab-paclitaxel for (N2) Defined NSCLC

The Efficacy and Safety of SerpinPC in Participants with Severe Hemophilia a or Moderately Severe to Severe Hemophilia B

The Effect of Alternative Keyboards on Discomfort and Typing Kinematics

Neurocognitive Factors in Substance Use Treatment Response: The Ways of Rewarding Abstinence Project

Rebeccamycin Analogue in Treating Patients With Advanced Liver and/or Biliary Cancer

Study Will Evaluate The Safety And Efficacy Of Anidulafungin In Patients With Candidemia Or Invasive Candidiasis

Vincristine, Dactinomycin, and Cyclophosphamide With or Without Radiation Therapy in Treating Patients With Newly Diagnosed Low-Risk Rhabdomyosarcoma

Lung Tissue Research Consortium

A Study of RoActemra/Actemra (Tocilizumab) Versus Placebo in Patients With Systemic Sclerosis

Study of Rezafungin Compared to Caspofungin in Subjects With Candidemia and/or Invasive Candidiasis

Feasibility of HIIT in Spinal Cord Injury

LTFU for Gene Transfer Subjects With Hemophilia B

A Study to Assess the Effect of CK-2127107 on Physical Function in Subjects With Chronic Obstructive Pulmonary Disease

PREPARE (A5361s) Ancillary Study of REPRIEVE (A5332)

Comparison of Efficacy, Safety, and Tolerability of ITCA 650 to Empagliflozin and Glimepiride as add-on Metformin

A Study in Participants With Acute Major Bleeding to Evaluate the Ability of Andexanet Alfa to Reverse the Anticoagulation Effect of Direct and Indirect Oral Anticoagulants (Extension Study)